ViroPharma Incorporated is an international biopharmaceutical company focused on developing and commercializing products for physician specialists or in hospital settings. The Company's marketed products include Cinryze TM and Vancocin'. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema (HAE), also known as C1 inhibitor (C1-INH) deficiency, a rare, severely debilitating, life-threatening genetic disorder. Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI), or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile. The Company sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. ViroPharma Incorporated is headquartered in Exton, Pennsylvania.
Market Value, $K:
Shares Outstanding, K:
% Held by Insiders:
% Institutional Shareholders:
Last Quarter Sales, $M:
Last Quarter Net Income, $M:
Last Quarter EPS:
Annual EPS, $:
Most Recent Earnings, $:
0.20 on 10/31/13
Annual Dividend Rate, $:
Most Recent Dividend:
Annual Dividend Yield, %:
Most Recent Split:
Fundamental information provided by Zacks Investment Research, Inc.
Zacks does not represent, warrant,
or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever
to any party on account of any incompleteness of, inaccuracies in or untimeliness of the Zacks content provided
hereunder, or for any delay in reporting such data. Zacks expressly disclaims all warranties of fitness of the
Zacks content or computations and analyses thereof for a particular purpose or use.